IFNG and neoplasm: Consistent with α-PD-1 not inducing PARP14 in responding tumours, PARP14i treatment failed to inhibit growth of tumours derived from IFNγ-naïve YUMM2.1 cells nor enhanced the activity of α-PD-1 when both drugs were co-administered (Supplementary Fig. 13A–C).